MedImaging

Download Mobile App
Recent News Radiography MRI Ultrasound Nuclear Medicine General/Advanced Imaging Imaging IT Industry News

New AI Software for Brain Bleed Diagnosis Receives FDA Clearance

By MedImaging International staff writers
Posted on 20 Nov 2018
Print article
Image: Product representations of the Accipio ICH detection software.
Image: Product representations of the Accipio ICH detection software.
The US Food and Drug Administration (FDA) has given 510(k) clearance to the Accipio Ix intracranial hemorrhage (ICH) detection software developed by MaxQ AI (Tel Aviv, Israel), a clinical diagnostics intelligence platform company.

This will provide healthcare providers and physicians in acute care settings with access to the artificial intelligence (AI) software which has been designed to aid in prioritizing the clinical assessment of adult non-contrast head computed tomography (CT) cases that exhibit indications of ICH, commonly known as a brain bleed.

MaxQ AI develops clinical diagnostic intelligent software solutions that enable timely and more accurate diagnosis as well as allow physicians to provide 'smarter care' with AI clinical insights. The company’s Accipio Ix ICH detection software leverages AI technology to automatically analyze non-contrast head CT images without workflow impact to the reader, altering the original series or storing Protected Health Information (PHI). Accipio Ix, part of MaxQ's Accipio INSIGHT platform, is designed to be highly sensitive to the presence of ICH, identifying and prioritizing patients with ICH for the treating physician. The AI-powered software provides the capability for rapid escalation and prioritization of the patient and can be natively integrated into CT and PACS systems using the imaging industry-standard DICOM, installed both on-premise and cloud-capable.

"MaxQ's Accipio application, of which Accipio Ix is the first part of the ecosystem, provides physicians with actionable intelligence, improving their future ability to make a timely, accurate and more confident diagnosis of a brain bleed," said Gene Saragnese, Chairman and CEO of MaxQ AI. "Accipio Ix's ability to greatly increase suspected bleed detection, improve escalation and time to review is a game-changer. Further, our partnerships with top CT and PACS companies, including GE Healthcare, Samsung Neurologica and other organizations prior announced, make deployment and adoption of Accipio straightforward."

Related Links:
MaxQ AI

Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
New
Ultrasound Table
Ergonomic Advantage (EA) Line
Ultrasound System
Acclarix AX9
New
Ultrasound System
Voluson Signature 18

Print article

Channels

Ultrasound

view channel
Image: CAM figures of testing images (Photo courtesy of SPJ; DOI:10.34133/research.0319)

Diagnostic System Automatically Analyzes TTE Images to Identify Congenital Heart Disease

Congenital heart disease (CHD) is one of the most prevalent congenital anomalies worldwide, presenting substantial health and financial challenges for affected patients. Early detection and treatment of... Read more

Nuclear Medicine

view channel
Image: Researchers have identified a new imaging biomarker for tumor responses to ICB therapy (Photo courtesy of 123RF)

New PET Biomarker Predicts Success of Immune Checkpoint Blockade Therapy

Immunotherapies, such as immune checkpoint blockade (ICB), have shown promising clinical results in treating melanoma, non-small cell lung cancer, and other tumor types. However, the effectiveness of these... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more